Media Articles Related to Opana (Oxymorphone)
Injecting Opioid Tied to Blood Clotting Disorder (CME/CE)
Source: MedPage Today Nephrology [2015.05.10]
(MedPage Today) -- Are most clinicians aware of this side effect of oxymorphone drug abuse?
American Pain Society (APS) 34th Annual Scientific Meeting
Source: Medscape Emergency Medicine Headlines [2015.05.15]
Read clinically focused news coverage of key developments from APS 2015.
ERs See Spike in Narcotic Painkiller Abuse Cases
Source: MedicineNet Drug Abuse Specialty [2015.05.14]
Title: ERs See Spike in Narcotic Painkiller Abuse Cases
Category: Health News
Created: 5/14/2015 12:00:00 AM
Last Editorial Review: 5/14/2015 12:00:00 AM
New research could lead to a blood test for common pain syndrome fibromyalgia
Source: Pain / Anesthetics News From Medical News Today [2015.05.13]
New UK research could lead to a blood test to diagnose the common pain condition, fibromyalgia.
Sacroiliac Joint Dysfunction (SI Joint Pain)
Source: MedicineNet Ankylosing Spondylitis Specialty [2015.05.13]
Title: Sacroiliac Joint Dysfunction (SI Joint Pain)
Category: Diseases and Conditions
Created: 10/31/2007 12:00:00 AM
Last Editorial Review: 5/13/2015 12:00:00 AM
Published Studies Related to Opana (Oxymorphone)
Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. [2011.05]
OBJECTIVE: To compare the subjective effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release (OC-CR)... CONCLUSIONS: At equianalgesic doses, single oral intact OM-ER produced lower positive, negative, and balance subjective effects than OC-CR, indicating that analgesic potency may not necessarily be reflected in subjective/objective effects.
Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone. [2010.11]
BACKGROUND: Opioids provide effective pain control, yet have risks including adverse events (AEs) (e.g., constipation, nausea/vomiting, sedation) and cognitive/psychomotor effects. OBJECTIVE: To compare cognitive and psychomotor effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release (OC-CR)... CONCLUSION: Single oral intact low and high doses of OM-ER produced less cognitive and psychomotor impairment plus less sedation than equianalgesic OC-CR in this exploratory study. ClinicalTrials.gov registration NCT00955110.
Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer. [2010.05]
OBJECTIVE: To evaluate the long-term safety, tolerability, and effectiveness of oxymorphone extended release (ER) in patients with cancer-related pain... CONCLUSIONS: In these patients with pain related to cancer, oxymorphone ER was generally well tolerated and provided stable long-term pain control.
The pain quality response profile of oxymorphone extended release in the treatment of low back pain. [2009.02]
OBJECTIVE: In controlled trials of analgesics, the primary outcome variable is most often a measure of global pain intensity. However, because pain is associated with a variety of pain sensations, the effects of analgesic treatments on different sensations could go undetected if specific pain qualities are not assessed...
Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use. [2009.02]
OBJECTIVE: This study assessed the potential effects of age, sex, and prior opioid use on the response to oxymorphone extended release (ER) in patients with moderate to severe chronic low back pain... CONCLUSION: In the enriched population of patients who successfully titrated to oxymorphone ER, oxymorphone ER was effective and generally well tolerated, independent of patients' age, sex, or previous opioid use.
Clinical Trials Related to Opana (Oxymorphone)
Effect of Extended-Release Oxymorphone Taking With or Without Food on Cognitive Functioning [Recruiting]
The purpose of the study is to determine whether extended-release oxymorphone hydrochloride
taken orally with a high-fat meal, generating an approximately 50% higher Cmax, impacts
cognitive functioning, using Cambridge Neuropsychological Test Automated Battery (CANTAB)
tests, to a greater extent than when taking under conditions of fasting.
Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects [Recruiting]
Patients will convert from current opioid to Oxymorphone ER and undergo titration. During
the Titration Period, subjects will receive daily oxymorphone Extended Release tablets(s)
every 12 hours. Dosing adjustments will be based on the review of the subject's pain
scores. Oxymorphone IR 5 mg will be provided to be used as supplemental "breakthrough" pain
medication (as needed). Titration Period will end when the fixed dose of study medication
is tolerated and the subject achieves adequate analgesia. Subjects will then proceed to the
open-label 3-month maintenance period on the fixed dose of study medication established
during the Titration Period.
Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects. [Recruiting]
When post-operative parenteral analgesia is discontinued, oral dosing with study medication
may begin once the subject has developed a moderate level of pain as defined by a 100 mm VAS
(pain intensity score greater than or equal to 40).
Lumbar Stenosis Outcomes Research II [Recruiting]
The primary objective of the proposed pilot study is to determine the efficacy of
oxymorphone hydrochloride and propoxyphene/acetaminophen combination in prolonging the time
to onset of pain and reducing the severity of pain associated with walking in patients with
neurogenic intermittent claudication. The secondary objective is to examine the functional
benefit of oxymorphone hydrochloride and propoxyphene/acetaminophen combination with respect
to improvement in duration and distance of walking tolerance.
The proposed study will also provide the foundation for a treadmill-based methodology for
assessing the analgesic efficacy of drugs for low back pain provoked by standing and walking
associated with lumbar spinal stenosis.
A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation) [Recruiting]
he purpose of this study is to see if changing from one pain medication like morphine or
oxycodone to another pain medication, oxymorphone (OPANAŽ), will be helpful to patients. This
study will examine if the swithcing from one pain medication to another can be done over a 24
hour period. Oxymorhone, the drug being studied, is an FDA approved drug for treatment of
Reports of Suspected Opana (Oxymorphone) Side Effects
Drug Abuse (22),
Drug Ineffective (20),
Weight Decreased (15),
Drug Dependence (15),
Respiratory Depression (12),
Intentional Drug Misuse (11),
Pain (10), more >>